touchEXPERT BRIEFING The evolving treatment landscape in relapsed/refractory multiple myeloma
Watch leading experts Shaji Kumar and Rahma Warsame discuss the current and evolving treatment landscape in relapsed/refractory multiple myeloma, as well as key factors influencing treatment decisions.
The current treatment landscape for relapsed/refractory multiple myeloma – what are the choices?
Shaji Kumar and Rahma Warsame discuss the key factors influencing treatment decisions in relapsed/refractory multiple myeloma, using a variety of patient scenarios.
view bio and disclosures 1/2 Next InterviewEvolution of relapsed/refractory multiple myeloma therapy – where are we headed?
Rahma Warsame and Shaji Kumar discuss the current landscape in relapsed/refractory multiple myeloma, and how treatment paradigms may evolve in the future.
view bio and disclosures 2/2 Leave FeedbackOverview & Learning Objectives
Overview
In recent years, the treatment landscape for multiple myeloma has evolved rapidly1. This has led to a complicated overall picture for treatment sequencing in the relapsed/refractory setting, involving a variety of patient-, tumour- and treatment-related factors1.
In addition, treatment becomes more challenging after each relapse, as multiple therapies enrich for resistant malignant clones and the cumulative toxicity of therapies increases, while bone marrow function decreases2. As such, achieving optimal treatment sequencing is key to preventing or delaying recurrent relapses following first-line therapy and improving patient prognosis2.
Learning Objectives
After watching this activity, participants should be better able to:
- Provide an overview of the treatment landscape for relapsed/refractory multiple myeloma (r/r MM).
- Describe key factors that influence treatment decisions and treatment sequencing in r/r MM.
- Discuss how new and developing treatments may impact the r/r MM treatment landscape and decision-making.
Faculty & Disclosures
Dr Shaji K Kumar
Division of Hematology, Mayo Clinic, Minnesota
The research of Shaji Kumar, M.D., focuses on development of novel drugs for treatment of myeloma. Dr Kumar’s research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma. Promising drugs are brought into the clinic through early-stage clinical trials in Phase I or II studies.
Dr Kumar also evaluates novel combinations of different drugs to identify synergistic combinations that can result in better treatment responses and eventually better patient outcomes. His work on drug development is complemented by an active program studying the biology of myeloma, with a focus on the study of bone marrow microenvironment in multiple myeloma and how it influences the tumor cells, especially the increased bone marrow microvessels seen in myeloma. His clinical research focuses on outcomes of patients with myeloma and amyloidosis, especially high-risk disease.
Dr Shaji Kumar discloses: Research funding for clinical trials to the institution from: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio and Molecular Templates; Consulting/Advisory Board participation (with no personal payments) from: Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium and (with personal payment) Oncopeptides, Beigene, Antengene and GLH Pharma.
Dr Rahma Warsame
Division of Hematology, Mayo Clinic, Minnesota
The research of Rahma Warsame, M.D., is focused on amyloidosis and multiple myeloma. Dr Warsame is interested in investigating existing health care delivery systems to improve patient-reported outcomes and quality of life. She is also working on incorporating patient perspectives into clinical practice and determining its effect on clinical outcomes.
Dr Rahma Warsame discloses: No known competing financial interests or personal relationships that could have appeared to influence the content of this activity.
References
- 1. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program 2020;2020:248–258.
- 2. Nikitorowicz-Buniak J. Sequencing treatments for relapsed/refractory multiple myeloma. Multiple Myeloma Hub 2022; available at https://multiplemyelomahub.com/medical-information/comy-2020-or-sequencing-treatments-for-relapsedrefractory-multiple-myeloma (accessed 22 December 2022).
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 9 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
